Sanofi SA (EPA:SAN)‘s stock had its “neutral” rating reiterated by investment analysts at J P Morgan Chase & Co in a research report issued to clients and investors on Thursday.
Several other research analysts also recently commented on the company. Morgan Stanley set a €92.00 ($108.24) price objective on Sanofi SA and gave the stock a “buy” rating in a research note on Friday, October 6th. S&P Global set a €90.00 ($105.88) price objective on Sanofi SA and gave the stock a “neutral” rating in a research note on Monday, July 31st. Goldman Sachs Group, Inc. (The) set a €82.00 ($96.47) price objective on Sanofi SA and gave the stock a “neutral” rating in a research note on Tuesday, October 17th. BNP Paribas set a €85.00 ($100.00) price objective on Sanofi SA and gave the stock a “neutral” rating in a research note on Tuesday, September 12th. Finally, Jefferies Group LLC set a €90.00 ($105.88) price objective on Sanofi SA and gave the stock a “neutral” rating in a research note on Monday, October 16th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating and five have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of €88.12 ($103.67).
ILLEGAL ACTIVITY NOTICE: “Sanofi SA (SAN) Rating Reiterated by J P Morgan Chase & Co” was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://sportsperspectives.com/2017/11/02/sanofi-sa-san-rating-reiterated-by-j-p-morgan-chase-co.html.
About Sanofi SA
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related companies with MarketBeat.com's FREE daily email newsletter.